Combining real-world clinical and genomic data resulted in a more accurate prediction of outcomes compared to examining clinical and...
SAN ANTONIO – For patients with “good-risk” ductal carcinoma in situ (DCIS) who underwent breast-conserving surgery and did not...
SAN ANTONIO – Patients with intermediate-risk breast cancer had similar rates of 10-year overall survival whether or not they...
Recurrence risk was similar between active monitoring and usual care groups SAN ANTONIO – Among patients with hormone receptor...
SAN ANTONIO – Patients with low-risk ductal carcinoma in situ (DCIS) who underwent active monitoring reported comparable physical, emotional,...
Imlunestrant was effective in combination with abemaciclib, and as monotherapy in ESR1-mutated breast cancer SAN ANTONIO – Imlunestrant, an investigational...
SAN ANTONIO – Patients with germline BRCA mutations who were diagnosed with breast cancer at or before age 40...
SAN ANTONIO – Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have...
SAN ANTONIO – The San Antonio Breast Cancer Symposium (SABCS) and the American Association for Cancer Research (AACR), an...
Combination of radiation, chemotherapy, and immunotherapy can shrink tumors and allow surgery, with much better survival rate rather than...